Seelaus Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Seelaus Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$458K	Sell	2,895 -285	-9%	-$38.5K	0.32%	91
2026 Q1	$406K	Hold	3,180	–	–	0.29%	107
2025 Q4	$388K	Sell	3,180 -50	-2%	-$5.73K	0.31%	93
2025 Q3	$324K	Hold	3,230	–	–	0.26%	114
2025 Q2	$268K	Sell	3,230 -108	-3%	-$8.62K	0.24%	131
2025 Q1	$271K	Sell	3,338 -325	-9%	-$29K	0.26%	121
2024 Q4	$330K	Sell	3,663 -1,359	-27%	-$132K	0.3%	105
2024 Q3	$496K	Sell	5,022 -217	-4%	-$21.3K	0.45%	69
2024 Q2	$486K	Buy	5,239 +231	+5%	+$20.7K	0.49%	63
2024 Q1	$475K	Buy	5,008 +40	+0.8%	+$3.71K	0.47%	71
2023 Q4	$444K	Buy	4,968 +321	+7%	+$23.8K	0.43%	81
2023 Q3	$339K	Sell	4,647 -475	-9%	-$37.9K	0.39%	91
2023 Q2	$426K	Buy	5,122 +835	+19%	+$69.8K	0.34%	105
2023 Q1	$349K	Buy	4,287 +90	+2%	+$7.47K	0.26%	122
2022 Q4	$348K	Buy	4,197 +259	+7%	+$21K	0.26%	127
2022 Q3	$312K	Buy	3,938 +20	+0.5%	+$1.69K	0.25%	135
2022 Q2	$291K	Buy	3,918 +73	+2%	+$5.48K	0.22%	144
2022 Q1	$346K	Sell	3,845 -2,563	-40%	-$237K	0.21%	156
2021 Q4	$717K	Buy	6,408 +1,820	+40%	+$220K	0.39%	73
2021 Q3	$577K	Buy	4,588 +400	+10%	+$51.5K	0.34%	89
2021 Q2	$567K	Buy	4,188 +850	+25%	+$112K	0.33%	100
2021 Q1	$453K	Sell	3,338 -525	-14%	-$78.6K	0.29%	109
2020 Q4	$544K	Hold	3,863	–	–	0.39%	80
2020 Q3	$430K	Hold	3,863	–	–	0.35%	89
2020 Q2	$432K	Sell	3,863 -150	-4%	-$14.8K	0.39%	81
2020 Q1	$311K	Hold	4,013	–	–	0.37%	85
2019 Q4	$382K	Sell	4,013 -66	-2%	-$5.71K	0.31%	93
2019 Q3	$311K	Sell	4,079 -190	-4%	-$15.8K	0.27%	101
2019 Q2	$374K	Hold	4,269	–	–	0.34%	84
2019 Q1	$387K	Hold	4,269	–	–	0.36%	85
2018 Q4	$306K	Buy	4,269 +35	+0.8%	+$2.82K	0.33%	89
2018 Q3	$406K	Sell	4,234 -750	-15%	-$72.7K	0.33%	93
2018 Q2	$474K	Sell	4,984 -550	-10%	-$50.5K	0.41%	77
2018 Q1	$485K	Buy	5,534 +78	+1%	+$7.12K	0.42%	79
2017 Q4	$463K	Buy	+5,456	New	+$457K	0.4%	76

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

Seelaus Asset Management's XBI Position: Q2 2026 in Review

Seelaus Asset Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 9% in Q2 2026, selling an estimated $38.5K and leaving 2,895 shares worth $458K. The position accounts for 0.32% of the portfolio, ranked #91.

Seelaus Asset Management first reported a position in XBI in Q4 2017 and has held it in 35 quarters since. The position peaked at $717K in Q4 2021. 403 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Seelaus Asset Management held 2,895 shares of State Street SPDR S&P Biotech ETF worth $458K as of Q2 2026.
Seelaus Asset Management sold 285 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $38.5K.
State Street SPDR S&P Biotech ETF made up 0.32% of Seelaus Asset Management's portfolio in Q2 2026, its #91 holding.
Seelaus Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 35 quarters since.
Seelaus Asset Management's State Street SPDR S&P Biotech ETF position peaked at $717K in Q4 2021.
403 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Seelaus Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.